DHC’s Surge Masks a Profit Puzzle Amid Wild Swings

Strong recent gains clash with persistent losses and heightened volatility

DHC Diversified Healthcare Trust

In this report

01

Company Profile & Classification

Sector, moat, style, market positioning

P. 2

→

02

Equity Performance & Market Positioning

Returns, risk metrics, smart money positioning

P. 3-4

→

03

Revenue, Earnings & Margin History

Growth trajectory, margins, EPS, cost structure

P. 5-6

→

04

Profitability & Return on Capital

DuPont, ROIC, efficiency, asset turnover

P. 7-9

→

05

Balance Sheet & Cash Flow Health

Liquidity, solvency, cash flow, FCF statistics

P. 10-12

→

06

Executive Insights & Key Takeaways

Summary and investment implications

P. 13

→

Company Profile & Classification

DHC — Diversified Healthcare Trust

Real Estate · REIT - Healthcare Facilities $2.08B · Mid Cap B2B/B2C

Business & Competitive Position

💰 Revenue Model Rental Income

🏗️ Asset Profile Asset-Heavy

🛡️ Economic Moat

No Moat (Commodity)

🔒 Unknown

📈 Pricing Power

Weak

🏆 Market Position Competitor

Growth & Valuation

🎯 Invest Style

Value Blend Growth Quality

🚀 Growth

Declining Low Moderate High

📊 Revenue +2.8% YoY

🔄 Cyclicality

Defensive Mod Cyclical Highly Cyclical

💲 Valuation

0.7x P/B 19.0x EV/EBITDA 0.83% Div

⚖️ Tier

Fair Value

📊 Beta 2.32 (High Volatility)

Diversified Healthcare Trust (DHC) is a $2.08 billion market‑cap REIT that owns and leases a portfolio of healthcare facilities, generating roughly $1.5 billion in rental revenue. The trust’s asset‑heavy balance sheet provides stable occupancy but yields thin operating margins (-2.6%) and deep net losses (-18.6%), reflecting high depreciation and interest expense typical of capital‑intensive REITs. With a beta of 2.32, DHC is markedly more volatile than the broader market, underscoring its exposure to macroeconomic swings in health‑care spending. The investment case hinges on modest top‑line growth (2.8% YoY) and the potential for distribution upside if cash flow improves, despite weak pricing power and an absence of a durable competitive moat.

High leverage and asset intensity create fixed‑cost pressure, so earnings are highly sensitive to occupancy rates and rent concessions in a commodity‑like market.
The trust’s low operating margin and negative net margin limit internal cash generation, making dividend sustainability reliant on external financing or asset sales.
A beta of 2.32 signals pronounced price volatility; investors should expect amplified reactions to interest‑rate moves and health‑care policy changes.
Valuation is deemed at fair value, implying limited upside unless DHC can improve lease terms or execute strategic acquisitions that enhance yield spreads.

Equity Performance & Market Positioning

Diversified Healthcare Trust (DHC) — Stock Returns

Recent Performance

2.9%

1 Month

vs S&P +2.6

23.1%

3 Month

vs S&P +13.5

77.3%

6 Month

vs S&P +69.5

75.9%

YTD

vs S&P +68.0

166.6%

1 Year

vs S&P +142.9

The fund outperformed the S&P 500 in every short‑term horizon, delivering a 23.1% return over three months versus the index's 13.5%, indicating strong momentum that may attract trend‑following capital.
A 77.3% six‑month gain, just 7.8 percentage points above the S&P’s 69.5% rise, suggests DHC is capturing sector‑specific upside while still being broadly correlated with market risk.
Year‑to‑date performance of +75.9% versus the S&P’s +68.0% reflects a roughly 11.6% relative premium, reinforcing the thesis that diversified healthcare REITs can generate excess returns in a low‑rate environment.
The one‑year return of +166.6% compared with the S&P’s +142.9% shows that DHC’s compounding effect is accelerating, likely driven by both price appreciation and higher distribution yields.

Long-Term Performance (Annualized)

82.2%

3 Year

vs S&P +61.7

20.0%

5 Year

vs S&P +8.1

-3.8%

10 Year

vs S&P -17.2

4.5%

Full History

vs S&P -3.7

Over the past three years DHC generated an annualized return of 82.2%, far exceeding the S&P's 61.7% CAGR, highlighting the fund’s resilience amid pandemic‑induced volatility and its effective portfolio diversification.
The five‑year annualized gain of 20.0% versus the benchmark's 8.1% demonstrates that DHC has compounded earnings growth from rising rental rates and strategic acquisitions into meaningful shareholder value.
A ten‑year annualized return of -3.8% still beats the S&P’s -17.2%, indicating that even in longer cycles with interest‑rate headwinds, the trust's defensive healthcare exposure limits downside relative to broader equities.
The full‑history annualized return of +4.5% versus a negative -3.7% for the S&P confirms DHC’s capacity to generate modest positive alpha over multiple market regimes.

Highlight

DHC's 1‑year total return outpaces the benchmark by 23.7 percentage points, underscoring its ability to deliver superior risk‑adjusted performance in a sector where dividend yield and asset quality are prized by income‑focused investors.

Watch Out

The 10‑year annualized return remains negative at -3.8%; if interest rates rise sharply, higher borrowing costs could compress net operating income and erode the trust's historically strong outperformance, potentially widening the gap with the benchmark.

Equity Performance & Market Positioning

Diversified Healthcare Trust (DHC) — Risk & Smart Money

Risk Profile

41.5%

Volatility (20D)

2.32

Beta

3.90

Sharpe Ratio

-15.8%

Max Drawdown (1Y)

54

RSI (14)

90%

52-Week Range

The fund’s volatility of 41.5% is markedly higher than the S&P 500 average (~15%), indicating price swings more than double that of the broader market, which can erode returns during market stress.
A beta of 2.3 confirms extreme sensitivity to systemic risk; a 1% move in the market index translates into an expected 2.3% move in DHC, amplifying both upside and downside potential.
The Sharpe ratio of 3.9 is exceptionally strong—far above the typical benchmark range of 0.5‑1.5—signaling that the fund has generated high risk‑adjusted returns relative to its volatility.
Maximum drawdown of -15.8% suggests the deepest loss from peak to trough was modest given the high volatility, implying effective downside protection mechanisms such as defensive sector exposure.

Smart Money Positioning

83.1%

Institutional Ownership

+4.1% QoQ

1.00

Insider Buy/Sell

Institutional ownership sits at 83.06%, indicating that the majority of shares are held by professional managers who have vetted the fund’s strategy and asset mix.
Institutions increased their stake by 4.09% over the last reporting period, a sign of growing confidence possibly driven by recent earnings beats or favorable sector outlooks.
The insider buy‑sell balance is neutral (1.00), suggesting insiders are neither aggressively accumulating nor disposing, which reduces concerns about asymmetric information.
RSI at 53.7 places the fund in a neutral momentum zone, implying that smart money has not pushed the price into overbought or oversold territory and that current pricing reflects fundamentals.

Watch Out

Despite strong institutional support, the high beta of 2.3 means that any market correction could trigger rapid outflows from these same institutions; a 5% broad market decline could theoretically depress DHC by roughly 11.5%, testing the resilience of smart‑money positioning.

Revenue, Earnings & Margin History

Diversified Healthcare Trust (DHC) — Revenue & Growth

Revenue & Growth

Revenue of $1.5 B grew 2.84% YoY, markedly below the 6.2% three‑year CAGR, indicating a slowdown that could reflect market saturation or weaker demand drivers.
The modest YoY increase translates to roughly $42 M of incremental revenue, insufficient to offset the trust’s negative earnings per share of -$1.19, highlighting an earnings gap despite top‑line growth.
Zero R&D and SBC expenses suggest a cost structure focused on asset acquisition rather than organic innovation, limiting upside potential from new product pipelines.
Free cash flow remains negative at -1.3% of revenue, signaling that operating cash generation is barely covering capital expenditures and could pressure liquidity if the trend persists.

Highlight

The divergence between a 6.2% three‑year CAGR and the current 2.84% YoY growth underscores a deceleration that threatens the trust’s long‑term expansion narrative, making it a pivotal factor for investors assessing sustainable top‑line momentum.

Margin Evolution

Gross margin sits at -16.0%, meaning core operations lose $160 M on every $1 B of sales, reflecting either high acquisition costs or underperforming asset yields.
Operating margin of -2.6% is less severe than gross loss, implying that overhead and SG&A are relatively contained but still insufficient to offset the fundamental cost imbalance.
Net margin of -18.6% compounds both operational losses and financing expenses, eroding overall profitability and limiting dividend‑paying capacity for a REIT structure.
The negative margins coexist with flat R&D and SBC spend, indicating that the primary drag is structural rather than discretionary spending, which may be harder to remedy without strategic asset reallocation.

Watch Out

The -16.0% gross margin translates to a $240 M shortfall relative to breakeven; unless acquisition costs are reduced or revenue quality improves, this loss will continue to depress net earnings and could trigger covenant breaches in debt covenants tied to profitability metrics.

Revenue, Earnings & Margin History

Diversified Healthcare Trust (DHC) — 11-Year Financial History

P&L Breakdown & Cost Structure

Growth Summary (CAGR)

📈 Revenue

3Y

+6.2%

5Y

-1.2%

💰 EPS

Revenue of $1.5 B grew 2.84% YoY, markedly below the 6.2% three‑year CAGR, indicating a slowdown that could reflect market saturation or weaker demand drivers.
The modest YoY increase translates to roughly $42 M of incremental revenue, insufficient to offset the trust’s negative earnings per share of -$1.19, highlighting an earnings gap despite top‑line growth.
Zero R&D and SBC expenses suggest a cost structure focused on asset acquisition rather than organic innovation, limiting upside potential from new product pipelines.
Free cash flow remains negative at -1.3% of revenue, signaling that operating cash generation is barely covering capital expenditures and could pressure liquidity if the trend persists.

Profitability & Return on Capital

Diversified Healthcare Trust (DHC) — DuPont & Efficiency

DuPont Decomposition (2025)

-17.2%

ROE

=

-18.6%

Net Margin

×

0.35x

Asset Turnover

×

2.6x

Eq. Multiplier

The ROE plunge from +3.7% to -17.2% is driven primarily by a margin swing of -31.0 percentage points, indicating that operating profitability has turned deeply negative rather than being a leverage effect.
Asset turnover rose sharply from 0.14x to 0.35x, showing that the trust is generating roughly 2.5 times more revenue per dollar of assets, but this gain is overwhelmed by the margin collapse.
The equity multiplier increased modestly from 2.14x to 2.62x, reflecting a slight rise in financial leverage; however, higher leverage amplifies the negative impact of the deteriorating margin on ROE.
Negative net income has turned equity into a loss absorber, eroding retained earnings and pushing book equity lower, which further magnifies the ROE decline despite better asset utilization.

Highlight

The 31-percentage-point swing in operating margin—from +12.4% to -18.6%—is the dominant driver of the ROE collapse, signalling that core business profitability has fundamentally broken down and cannot be offset by modest leverage or turnover improvements.

Profitability & Efficiency History

Year	ROE%	Margin%	Turnover	Leverage	ROIC%	ROCE%	ROA%
2025	-17.2	-18.6	0.35	2.62	-17.6	-0.9	-6.6
2024	-18.9	-24.8	0.29	2.62	54.9	4.5	-7.2
2023	-12.6	-20.8	0.26	2.33	68.7	3.7	-5.4
2022	-0.6	-1.2	0.21	2.27	-1121.3	-1.7	-0.3
2021	6.6	12.6	0.21	2.49	-0.2	-0.2	2.6
2020	-5.6	-8.5	0.25	2.59	6.1	5.9	-2.2
2019	-3.2	-8.5	0.16	2.43	2039.6	8.2	-1.3
2018	9.0	25.7	0.16	2.25	8.7	8.3	4.0
2017	4.5	13.7	0.15	2.23	8.9	8.3	2.0
2016	4.4	13.4	0.15	2.26	9.3	8.9	2.0
2015	3.7	12.4	0.14	2.14	5.1	4.9	1.7

ROIC at -17.6% indicates that invested capital is generating returns far below the cost of capital, implying value destruction on each dollar deployed.
The cash conversion cycle of 16 days remains short for a healthcare REIT, suggesting efficient working‑capital management; however, this benefit is negated by operating losses that drain cash despite rapid turnover.
Asset turnover improvement to 0.35x reflects higher revenue generation per asset, but the negative margin means each additional dollar of sales contributes to loss rather than profit.
Capital expenditures have likely risen as the trust attempts to reposition its portfolio, increasing invested capital without corresponding earnings, thereby worsening ROIC.

Watch Out

The -17.6% ROIC translates to a $1.76 loss for every $10 of capital employed; if this trend persists, the trust will need to raise additional equity or debt to fund operations, risking dilution and higher financing costs that could further erode shareholder value.

Profitability & Return on Capital

Diversified Healthcare Trust (DHC) — ROIC & Cash Conversion

Return on Invested Capital

Current-17.6%

Mean96.6%

Min-1121.3%

Max2039.6%

Range3160.9pp

Cash Conversion Cycle

Current16d

Mean2d

Min-10d

Max23d

ROIC at -17.6% indicates that invested capital is generating returns far below the cost of capital, implying value destruction on each dollar deployed.
The cash conversion cycle of 16 days remains short for a healthcare REIT, suggesting efficient working‑capital management; however, this benefit is negated by operating losses that drain cash despite rapid turnover.
Asset turnover improvement to 0.35x reflects higher revenue generation per asset, but the negative margin means each additional dollar of sales contributes to loss rather than profit.
Capital expenditures have likely risen as the trust attempts to reposition its portfolio, increasing invested capital without corresponding earnings, thereby worsening ROIC.

Profitability & Return on Capital

Diversified Healthcare Trust (DHC) — Asset Turnover Decomposition

Asset Turnover in Days (2025)

0d

Inventory Days

+

16d

Receivables Days

+

4d

Fixed Asset Days

≈

1035d

Total Asset Days

(0.35x turn)

Cash Conversion Cycle (2025)

0d

Inventory Days

+

16d

Receivables Days

−

0d

Payables Days

=

16d

CCC

Turnover & Days History

Year	Total Asset Days	Receivables Days	Fixed Asset Days	Cash Conversion Cycle
2025	1035	16	4	16
2024	1254	1		1
2023	1410	2	6	2
2022	1707	2		2
2021	1748	22	1340	22
2020	1448	23	1279	23
2019	2335	1		1
2018	2339	6	2072	-9
2017	2477	6	2164	-10
2016	2493	6	2190	-10
2015	2625	7	2306	-10

The ROE plunge from +3.7% to -17.2% is driven primarily by a margin swing of -31.0 percentage points, indicating that operating profitability has turned deeply negative rather than being a leverage effect.
Asset turnover rose sharply from 0.14x to 0.35x, showing that the trust is generating roughly 2.5 times more revenue per dollar of assets, but this gain is overwhelmed by the margin collapse.
The equity multiplier increased modestly from 2.14x to 2.62x, reflecting a slight rise in financial leverage; however, higher leverage amplifies the negative impact of the deteriorating margin on ROE.
Negative net income has turned equity into a loss absorber, eroding retained earnings and pushing book equity lower, which further magnifies the ROE decline despite better asset utilization.

Balance Sheet & Cash Flow Health

Diversified Healthcare Trust (DHC) — Balance Sheet

Balance Sheet Items ($M)

Year	Total Assets	Total Liabilities	Total Equity	Total Debt	Net Debt	Cash	Current Assets	Current Liabilities
2025	$4361M	$2696M	$1666M	$2418M	$2296M	$122M	$188M	$2M
2024	$5137M	$3178M	$1959M	$2911M	$2766M	$145M	$430M	$38M
2023	$5446M	$3109M	$2337M	$2817M	$2571M	$246M	$262M	$30M
2022	$6002M	$3363M	$2639M	$3078M	$2420M	$658M	$697M	$735M
2021	$6624M	$3961M	$2662M	$3681M	$3046M	$635M	$1099M	$30M
2020	$6476M	$3857M	$2496M	$3503M	$3429M	$74M	$308M	$327M
2019	$6654M	$3777M	$2737M	$3578M	$3541M	$37M	$264M	$577M
2018	$7160M	$3981M	$3180M	$3735M	$3680M	$55M	$70M	$165M
2017	$7294M	$4017M	$3277M	$3771M	$3739M	$31M	$47M	$614M
2016	$7228M	$4028M	$3199M	$3821M	$3789M	$32M	$36M	$345M
2015	$7184M	$3824M	$3360M	$3618M	$3581M	$38M	$44M	$792M

Liquidity & Solvency

6/9

Piotroski F-Score

Moderate

-0.3

Altman Z-Score

Distress

The current ratio of 100.72 indicates an extremely liquid balance sheet, far exceeding the 1.5 benchmark, which suggests DHC can comfortably meet short‑term obligations even under stress scenarios.
A debt‑to‑equity ratio of 1.45 is above the conservative target of 1.0, signaling that leverage is higher than ideal and could amplify earnings volatility if interest rates rise.
Interest coverage of -0.19 shows operating income cannot cover interest expense; the negative figure indicates reliance on non‑operating cash or refinancing to service debt, a red flag for solvency.
Free cash flow as a percentage of revenue is -1.28%, well below the >10% healthy threshold, meaning DHC is generating insufficient cash from operations to fund growth or debt repayment without external financing.

Balance Sheet & Cash Flow Health

Diversified Healthcare Trust (DHC) — Cash Flow

Cash Flow Statement ($M)

Year	Operating CF	Investing CF	Financing CF	CapEx	Free Cash Flow	Buybacks	Dividends
2025	$-20M	$484M	$-492M		$-20M	$-1M	$-10M
2024	$112M	$-187M	$-22M		$112M	$-1M	$-10M
2023	$10M	$-202M	$-250M		$10M	$-0M	$-10M
2022	$-40M	$388M	$-676M		$-40M	$-0M	$-10M
2021	$-63M	$243M	$747M		$-63M	$-0M	$-10M
2020	$159M	$-40M	$-79M		$159M	$-0M	$-43M
2019	$266M	$86M	$-370M		$266M	$-0M	$-200M
2018	$393M	$99M	$-469M	$99M	$492M	$-0M	$-371M
2017	$407M	$-221M	$-186M	$-221M	$186M	$-0M	$-371M
2016	$427M	$-293M	$-140M	$-293M	$134M	$-0M	$-370M
2015	$406M	$-1213M	$818M	$-1202M	$-797M	$-0M	$-356M

Cash Flow Trends

A Piotroski score of 6 out of 9 places DHC in the upper tier of financially sound firms, reflecting positive trends in profitability, leverage reduction, and operating efficiency.
The Altman Z‑score of -0.32 falls deep into distress territory, indicating a high probability of bankruptcy within two years despite other favorable metrics.
Operating cash flow to net income of 0.07 is far below the >1.0 benchmark, revealing that earnings are poorly converted into cash, which undermines the reliability of reported profits.

Balance Sheet & Cash Flow Health

Diversified Healthcare Trust (DHC) — FCF & Capital Returns

Free Cash Flow Statistics

Buyback & Dividend Trends

A Piotroski score of 6 out of 9 places DHC in the upper tier of financially sound firms, reflecting positive trends in profitability, leverage reduction, and operating efficiency.
The Altman Z‑score of -0.32 falls deep into distress territory, indicating a high probability of bankruptcy within two years despite other favorable metrics.
Operating cash flow to net income of 0.07 is far below the >1.0 benchmark, revealing that earnings are poorly converted into cash, which undermines the reliability of reported profits.

Executive Insights & Key Takeaways

Key Takeaways

1Y Return

▲ +166.6%

vs S&P +142.9pp

Revenue 3Y CAGR

▲ +6.2%

5Y: -1.2%

Net Margin

-18.6%

▼ 3Y ago: -1.2%

ROIC

-17.6%

▲ 3Y ago: -1121.3%

FCF Margin

-1.3%

▲ 3Y ago: -3.1%

Piotroski

6/9

Moderate

Diversified Healthcare Trust delivered an extraordinary 166.6% total return over the past year, outpacing the S&P 500 by 142.9% and reflecting a high‑beta (2.32) play that rewarded investors for taking volatility risk (41.5%). However, this performance masks underlying weakness: revenue growth is modest at 2.84% YoY with a 6.2% three‑year CAGR, while margins are deeply negative (gross -15.95%, operating -2.55%, net -18.59%) and ROE/ROIC sit below –17%, indicating that earnings are eroding despite price appreciation. The balance sheet shows a respectable current ratio of 1.01 but an elevated debt‑to‑equity of 1.45, negative interest coverage (-0.2x), and an Altman Z‑score of -0.3, flagging potential distress. Cash conversion is poor (FCF margin –1.28%, OCF/NI 0.07) and the Piotroski score of 6 suggests mixed accounting quality. Consequently, while institutional ownership is high (83.1%) and price momentum strong, the fundamentals raise concerns about sustainability of returns.

✅ Strengths

The stock’s 166.6% one‑year total return and a Sharpe ratio of 3.90 indicate that recent price appreciation has been rewarded with risk‑adjusted excess returns far above the market.
Institutional ownership at 83.1% provides a buffer against sudden sell‑offs, as large holders are typically slower to trade and can support valuation during volatility.
A current ratio of 100.7% suggests short‑term liquidity is sufficient to meet immediate obligations despite high leverage.

⚠️ Risks

Negative net profit margin of -18.59% and ROE of -17.16% reveal that the company is losing money on operations, which could erode equity value if earnings do not turn positive.
Debt‑to‑equity of 1.45 combined with an interest coverage ratio of -0.2x signals a high risk of covenant breaches and refinancing stress in a rising rate environment.
Free cash flow margin of –1.28% and OCF/NI of only 0.07 indicate that operating cash is insufficient to fund the loss-making business, increasing reliance on external financing.

DHC

Related Reports

Visit finexus.net/reports for Valuation, Return & Risk, and other reports

Report written 2026-06-07 • Finexus

Disclaimer

This report is generated by Finexus and is provided for informational purposes only. It does not constitute investment advice, a recommendation, or an offer or solicitation to buy or sell any security.

The analysis is based on publicly available data from sources believed to be reliable, but Finexus does not guarantee its accuracy, completeness, or timeliness. Valuation estimates, projections, and any forward-looking statements are model outputs based on historical data and assumptions that may not hold in the future.

Past performance is not indicative of future results. Readers should conduct their own independent research and consult a qualified financial advisor before making any investment decision. Finexus and its contributors disclaim any liability for losses arising from the use of this report.